How many institutions own JSPRW stock?

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own JSPRW shares is N/A, representing N/A of the company's common stock.

Who are the major shareholders selling Jasper Therapeutics, Inc. stock?

N/A, in the last quarter, reduced its stake in JSPRW by N/A restricting it's holding to - shares of worth nearly -. N/A also lessened N/A of the JSPRW shares from its portfolio, reducing its holding to - shares of worth -. N/A also shunned JSPRW shares holding by N/A last quarter which brought its holding to - shares worth -.

Investors who are buying JSPRW stock?

As per its latest 13F filing, N/A increased its stake in JSPRW by N/A in the last quarter. The institutional holder raised its holding to - shares having worth more than -. N/A also added N/A more shares of JSPRW to its portfolio, raising its holding to - shares of worth -. N/A also increased its JSPRW shares holding by N/A which brought its holding to - shares worth -.

JSPRW's major insiders: who are they?

The insider with the most stakes in JSPRW is Carlyle Group Inc. , 10 percent owner at the company. Additionally, JSPRW stock is highly held by 10 percent owner Qiming U.S. Healthcare Fund II, L.P. and director ROCHE HOLDING LTD among others.

Did an insider recently sell JSPRW stock?

Company executives, directors, and other insiders own N/A percent of Jasper Therapeutics, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which JSPRW insiders have sold stock, totaling 0 shares. Insiders that have sold shares include LIS WILLIAM, MAHAL JEETINDER SINGH, and FRENCH ANNA LOUISE.

Which insider recently purchased JSPRW stock?

There have been 0 transaction(s) during the past 6-months in which Jasper Therapeutics, Inc. insiders have bought stock, totalling 0 shares

How much of JSPRW does insiders own?

Around 0 Jasper Therapeutics, Inc. shares are held by insiders, which represents about N/A of JSPRW stock.

Who is the insider with the largest stake?

JSPRW 10 percent owner, Carlyle Group Inc. holds the largest portfolio of the company's shares. JSPRW shares owned by Carlyle total nearly 8.76 million.

Which institution holds the most shares in JSPRW?

N/A is the largest institutional owner in JSPRW which holds - shares worth - or N/A of the total JSPRW shares outstanding followed by N/A with ownership of - shares representing N/A of the JSPRW ownership. N/A is the third largest stakeholder with - shares or N/A of the ownership worth more than -.

Is Jasper Therapeutics, Inc. stock optionable?

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the JSPRW is concerned, it is a stock which is optionable.

Is there a short position on JSPRW's shares?

Number of JSPRW shares short is N/A. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

About how many outstanding JSPRW shares are there?

As of today, N/A shares of JSPRW are outstanding.

Is there many float in JSPRW stock?

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, JSPRW has N/A shares in float.

JSPRW short ratio: what is it?

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for JSPRW is N/A.

Stock Ideas

JSPRW Stock Ownership Breakdown

NASDAQ : JSPRW

Jasper Therapeutics

$0.01

0.001099+14.85%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stock Outstanding Shares

Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.

N/A

Short % of Float

N/A

Short % of Shares Outstanding

Institutional Ownership

Date	Holder	% Stake	Shares Held	Total Value ($)	Shares	% Change in Portfolio
No Data

Insiders

Among the JSPRW insiders holding of N/A of the stake in company, CARLYLE GROUP INC., 10 percent owner, holds the largest shares of 8.76M. QIMING U.S. HEALTHCARE FUND II, L.P., 10 percent owner, is the second largest JSPRW insider with ownership of 8.52M shares. ROCHE HOLDING LTD, director, stands third with possession of 4.55M shares of that stake.

Insiders	Designation	Shares Held
CARLYLE GROUP INC.	10 percent owner	8.76M
QIMING U.S. HEALTHCARE FUND II, L.P.	10 percent owner	8.52M
ROCHE HOLDING LTD	director	4.55M
GLAZER CAPITAL, LLC	10 percent owner	895.06K
MAHAL JEETINDER SINGH	See Remarks	287.22K
LIS WILLIAM	director	53.52K
WIGGANS THOMAS G	director	50K
FRENCH ANNA LOUISE	director	23.75K
EMSTER KURT VON	director	21.18K

Buying/Selling by Insiders

Date	Insider	Type	Cost	Shares	Value ($)	Shares Total
Nov 28, 2023	WIGGANS THOMAS G	PURCHASE	0.65	10K	6.49K	50K
Nov 21, 2023	WIGGANS THOMAS G	PURCHASE	0.64	10K	6.38K	40K
Nov 20, 2023	WIGGANS THOMAS G	PURCHASE	0.63	10K	6.31K	30K
Nov 17, 2023	WIGGANS THOMAS G	PURCHASE	0.60	10K	5.97K	20K
Nov 16, 2023	WIGGANS THOMAS G	PURCHASE	0.60	10K	5.97K	10K
Oct 13, 2023	LIS WILLIAM	SALE	0.85	7.97K	6.78K	53.52K
Jun 13, 2023	MAHAL JEETINDER SINGH	SALE	1.66	9K	14.91K	287.22K
Apr 14, 2023	FRENCH ANNA LOUISE	SALE	1.48	7K	10.36K	23.75K
Apr 13, 2023	EMSTER KURT VON	SALE	1.49	9.08K	13.52K	21.18K
Apr 13, 2023	LIS WILLIAM	SALE	1.44	8.5K	12.24K	61.49K
Jan 27, 2023	CARLYLE GROUP INC.	PURCHASE	1.50	3.13M	4.7M	8.76M
Jan 27, 2023	QIMING U.S. HEALTHCARE FUND II, L.P.	PURCHASE	1.50	2.67M	4M	8.52M
Jan 25, 2023	ROCHE HOLDING LTD	SALE	1.89	75K	141.75K	4.55M
Apr 23, 2021	GLAZER CAPITAL, LLC	SALE	9.92	151.72K	1.51M	895.06K
Apr 21, 2021	GLAZER CAPITAL, LLC	SALE	9.92	1.16K	11.55K	1.05M
Apr 19, 2021	GLAZER CAPITAL, LLC	SALE	9.97	2.06K	20.54K	1.05M
Feb 22, 2021	GLAZER CAPITAL, LLC	SALE	10.50	698	7.33K	1.05M
Feb 19, 2021	GLAZER CAPITAL, LLC	SALE	10.50	2.11K	22.18K	1.05M
Feb 18, 2021	GLAZER CAPITAL, LLC	SALE	10.45	10K	104.5K	1.05M
Feb 05, 2021	GLAZER CAPITAL, LLC	SALE	10.40	212	2.2K	1.06M
Jan 14, 2021	GLAZER CAPITAL, LLC	SALE	10.40	101	1.05K	1.06M
Jan 08, 2021	GLAZER CAPITAL, LLC	SALE	10.25	10K	102.5K	1.06M
Dec 30, 2020	GLAZER CAPITAL, LLC	SALE	10.25	75	768.75	1.07M
Dec 29, 2020	GLAZER CAPITAL, LLC	SALE	10.25	18	184.5	1.07M
Dec 28, 2020	GLAZER CAPITAL, LLC	SALE	10.20	10K	102K	1.07M
Dec 22, 2020	GLAZER CAPITAL, LLC	SALE	10.15	10K	101.5K	1.08M
Dec 15, 2020	GLAZER CAPITAL, LLC	SALE	10.15	10K	101.5K	1.09M
Dec 14, 2020	GLAZER CAPITAL, LLC	SALE	10.05	5K	50.25K	1.1M
Dec 11, 2020	GLAZER CAPITAL, LLC	SALE	10.05	5K	50.25K	1.11M
Dec 07, 2020	GLAZER CAPITAL, LLC	SALE	10.05	1	10.05	1.11M
Sep 21, 2020	GLAZER CAPITAL, LLC	SALE	10.00	1K	10K	1.11M
Sep 18, 2020	GLAZER CAPITAL, LLC	SALE	10.00	1K	10K	1.11M
Sep 16, 2020	GLAZER CAPITAL, LLC	SALE	9.99	20	199.8	1.12M
Sep 15, 2020	GLAZER CAPITAL, LLC	SALE	9.99	800	7.99K	1.12M
Sep 11, 2020	GLAZER CAPITAL, LLC	SALE	9.99	682	6.81K	1.12M
Sep 08, 2020	GLAZER CAPITAL, LLC	SALE	9.99	1	9.99	1.12M
Sep 04, 2020	GLAZER CAPITAL, LLC	SALE	10.73	11	118.03	1.11M
Aug 17, 2020	GLAZER CAPITAL, LLC	SALE	9.99	1.7K	16.97K	1.12M
Aug 13, 2020	GLAZER CAPITAL, LLC	SALE	9.99	1.7K	16.97K	1.12M

Frequently Asked Questions

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.